Skip to content
Bleomycin
Blenoxane (bleomycin) is a small molecule pharmaceutical. Bleomycin was first approved as Blenoxane on 1982-01-01. It is used to treat choriocarcinoma, hodgkin disease, melanoma, non-hodgkin lymphoma, and sarcoma amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
endocrine system diseasesD004700
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bleomycin sulfate
Tradename
Company
Number
Date
Products
BLENOXANEBristol Myers SquibbN-050443 DISCN1982-01-01
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
bleomycinunapproved drug for use in drug shortage2022-12-27
bleomycinunapproved drug for use in drug shortage2022-12-27
bleomycinunapproved drug for use in drug shortage2022-12-27
bleomycinunapproved drug for use in drug shortage2022-12-27
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
choriocarcinoma—D002822C58
hodgkin disease—D006689C81
melanoma—D008545—
non-hodgkin lymphoma—D008228C85.9
sarcoma—D012509—
squamous cell carcinoma—D002294—
teratocarcinoma—D018243—
testicular neoplasms—D013736C62
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01D: Cytotoxic antibiotics and related substances
— L01DC: Other cytotoxic antibiotics in atc
— L01DC01: Bleomycin
HCPCS
Code
Description
J9040
Injection, bleomycin sulfate, 15 units
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBLEOMYCIN
INNbleomycin
Description
Bleomycin A2 is a bleomycin. It has a role as an antineoplastic agent and a metabolite.
Classification
Small molecule
Drug classantibiotics (Streptomyces strain)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1
Identifiers
PDB—
CAS-ID11056-06-7
RxCUI1622
ChEMBL IDCHEMBL403664
ChEBI ID3139
PubChem CID5460769
DrugBankDB00290
UNII ID40S1VHN69B (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 42,166 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3 adverse events reported
View more details